Sex, statins, and statistics

The Lancet

Volumn 385, Issue 9976, 2015, Pages 1368-1369

  Mosca, Lori ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADVERSE OUTCOME; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DIABETES MELLITUS; FOLLOW UP; HIGH RISK POPULATION; HUMAN; LOW RISK POPULATION; MYOPATHY; NOTE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHABDOMYOLYSIS; RISK REDUCTION; SCIENTIST; SEX; SEX DIFFERENCE; STATISTICS; BLOOD; CARDIOVASCULAR DISEASES; FEMALE; MALE;

CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE;

EID: 84928694538     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)62005-5     Document Type: Note

References (12)

1. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials. Lancet 2015; published online Jan 9. http://dx.doi.org/10.1016/S0140-6736(14)61368-4.
2. Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581-90.
3. Kostis WJ, Cheng JQ, Dobrzynski J.M., Cabrera J., Kostis JB. Meta-analysis of statin effects in women versus men. J Am Coll Cardiol 2012; 59: 572-82.
4. Taylor F, Huffman MD, Mecado A.F., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013; 1: CD004816.
5. Culver AL, Ockene IS, Balasubramanian R, et al Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 2012; 172: 144-52.
6. Sattar N, Priess D, Murray H.M., et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-42.
7. Institute of Medicine. Women's health research: progress, pitfalls, and promise. Washington, DC: The National Academies Press, 2010.
8. Healy B. The Yentl syndrome. N Engl J Med 1991; 325: 274-76.
9. Mosca L, Linfante AH, Benjamin E.J., et al. Physician awareness and adherence to cardiovascular disease prevention guidelines in the United States. Circulation 2005; 111: 499-510.
10. Mosca L, Benjamin EJ, Berra K, et al Effectiveness-based guidelines for the prevention of cardiovascular disease in women - 2011 update: a guideline from the American Heart Association. J Am Coll Cardiol 2011; 57: 1404-23.
11. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385: 117-71.
12. Kotseva K, Wood D, De Backer G, for the EUROASPIRE Study Group. EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. Eur J Cardiovasc Prev Rehabil 2010; 17: 530-40.